These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12606067)

  • 21. Neuroprotective effects of Danshensu in Parkinson's disease mouse model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Han B; Che X; Zhao Y; Li C; He J; Lu Y; Wang Z; Wang T
    Behav Pharmacol; 2019 Feb; 30(1):36-44. PubMed ID: 29847337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Running wheel activity restores MPTP-induced functional deficits.
    Fredriksson A; Stigsdotter IM; Hurtig A; Ewalds-Kvist B; Archer T
    J Neural Transm (Vienna); 2011 Mar; 118(3):407-20. PubMed ID: 20852902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
    Sundström E; Fredriksson A; Archer T
    Brain Res; 1990 Oct; 528(2):181-8. PubMed ID: 2271921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
    Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
    Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
    Fredriksson A; Archer T
    Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
    Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
    Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consequences of manganese administration for striatal dopamine and motor behavior in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed C57BL/6 mice.
    Dodd CA; Bloomquist JR; Klein BG
    Hum Exp Toxicol; 2013 Aug; 32(8):865-80. PubMed ID: 23263854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
    Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
    J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
    Rommelfanger KS; Edwards GL; Freeman KG; Liles LC; Miller GW; Weinshenker D
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13804-9. PubMed ID: 17702867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Singh A; Verma P; Balaji G; Samantaray S; Mohanakumar KP
    Neurochem Int; 2016 Oct; 99():221-232. PubMed ID: 27395789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
    Rozas G; López-Martín E; Guerra MJ; Labandeira-García JL
    J Neurosci Methods; 1998 Sep; 83(2):165-75. PubMed ID: 9765130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia.
    Fisher BE; Petzinger GM; Nixon K; Hogg E; Bremmer S; Meshul CK; Jakowec MW
    J Neurosci Res; 2004 Aug; 77(3):378-90. PubMed ID: 15248294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
    Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
    Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.